Trial record 1 of 1 for:    NCT00901901
Previous Study | Return to List | Next Study

Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma (SEARCH)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT00901901
First received: May 13, 2009
Last updated: July 9, 2014
Last verified: July 2014

May 13, 2009
July 9, 2014
May 2009
April 2012   (final data collection date for primary outcome measure)
Overall Survival [ Time Frame: From randomization of the first patient until 34 months or date of death of any cause whichever came first ] [ Designated as safety issue: No ]
Overall Survival (OS) was defined as the time from date of randomization to death due to any cause.
Overall Survival measured via patient phone contacts after treatment is complete [ Time Frame: From the date of randomization until th date of death due to any cause ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00901901 on ClinicalTrials.gov Archive Site
  • Time to Radiological Tumor Progression (TTP) [ Time Frame: From randomization of the first participant until 34 months later (cut-off date), assessed every 6 weeks ] [ Designated as safety issue: No ]
    TTP was the time from randomization to radiological tumor progression. Participants without radiological tumor progression at the time of analysis were censored at their last date of tumor evaluation. Progressive disease (PD) was defined using Response Evaluation Criteria in Solid Tumors (RECIST version 1.0), as at least a 20% increase in the sum of longest diameter (LD) of measured lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions. Appearance of new lesions also constituted PD.
  • Disease Control [ Time Frame: From randomization of the first participant until 34 months later (cut-off date), assessed every 6 weeks ] [ Designated as safety issue: No ]
    Disease control was defined as the number of participants who had a best response rating of complet response (CR), partial response (PR), or stable disease (SD) according to RECIST assessed by magnetic resonance imaging (MRI) that was confirmed at least 28 days from the first demonstration of that rating. CR: disappearance of all clinical and radiological evidence of target and non-target tumors. PR: at least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD. SD: steady state of disease. Neither sufficient shrinkage for PR nor sufficient increase for PD.
  • Health-related Quality of Life and Utility Values as Measured by EQ-5D - Index [ Time Frame: The EQ-5D was administered at the beginning of the visit prior to seeing the investigator. Questionnaires were to be completed every 6 weeks (Day 1 of each cycle) for subsequent cycles and at the end of treatment visit. ] [ Designated as safety issue: No ]
    The European quality of life scale (5 dimensions) (EQ-5D) questionnaire was given to the participants at each visit. The EQ-5D questionnaire consisted of 5 ordinal categorical responses (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). The scores for the EQ-5D dimensions are assigned according to the level of problems reported (1 'no problems'; 2 'some problems'; 3 'extreme problems'). The 5 health dimensions are summarized into a single score, the EQ-5D index score. The EQ-5D index score has a range of 0 and 1 with 0 representing death and 1 representing perfect health.
  • Health-related Quality of Life and Utility Values as Measured by EQ-5D - VAS [ Time Frame: The EQ-5D VAS was administered at the beginning of the visit prior to seeing the investigator. Questionnaires were to be completed every 6 weeks (Day 1 of each cycle) for subsequent cycles and at the end of treatment visit. ] [ Designated as safety issue: No ]
    Participants indicated on a scale of 0 (worst) to 100 (best) how good or bad their health state was on that particular day.
  • Time to Progression, response rate, duration of response, disease control rate determined by tumor measurement using MRI or CT scans [ Time Frame: Every 6 weeks during treatment ] [ Designated as safety issue: No ]
  • Health Related Quality of Life and Utility Values as measured by the EQ-5D [ Time Frame: Every 6 weeks during treatment ] [ Designated as safety issue: No ]
  • Laboratory testing [ Time Frame: Every 3 weeks during treatment ] [ Designated as safety issue: Yes ]
  • AE reporting [ Time Frame: Every 3 weeks during treatment ] [ Designated as safety issue: Yes ]
  • ECG [ Time Frame: At the start and at the completion of treatment ] [ Designated as safety issue: Yes ]
  • Vital signs [ Time Frame: Every 3 weeks during treatment ] [ Designated as safety issue: Yes ]
  • Duration of Response [ Time Frame: From randomization of the first participant until 34 months later (cut-off date), assessed every 6 weeks ] [ Designated as safety issue: No ]
    Duration of response - RECIST: number of days from the date that CR or PR is first documented to date that PD is first objectively documented or to death before progression. Note: the relevant date is that of the first documentation, not the confirmation date (if participant progressed or died then censored=no) or to last observation if participant did not progress or die then censored=yes note: this last observation date should be the same as that used for time to progression.
  • Time to Response [ Time Frame: From randomization of the first participant until 34 months later (cut-off date), assessed every 6 weeks ] [ Designated as safety issue: No ]
    Time to response was the number of days from randomization to the date the CR or PR was documented (with confirmation) (Note: the relevant date is that of the first documentation, not the confirmation date).
  • Tumor Response [ Time Frame: From randomization of the first participant until 34 months later (cut-off date), assessed every 6 weeks ] [ Designated as safety issue: No ]
    Tumor response was the proportion of participants with the best tumor response (ie, achieving either a confirmed complete response [CR] or partial response [PR], according to Response Evaluation Criteria in Solid Tumors [RECIST] criteria).
Not Provided
 
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
A Phase III Randomized, Placebo Controlled, Double Blind Trial of Sorafenib Plus Erlotinib vs. Sorafenib Plus Placebo as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC)

This is a randomized trial to evaluate the clinical benefit of sorafenib 400 mg twice daily and erlotinib 150 mg once a day versus sorafenib 400 mg twice daily and placebo erlotinib once daily in subjects with unresectable advanced or metastatic Child-Pugh A HCC. Patients who are candidates for potentially curative intervention (i.e. surgical resection or local ablation) are not eligible for this study.

European quality of life scale (5 dimensions) (EQ-5D)

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Carcinoma, Hepatocellular
  • Drug: Sorafenib (Nexavar, BAY43-9006)
    Sorafenib 400 mg twice daily + matching erlotinib placebo daily
  • Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
    Sorafenib 400 mg twice daily + erlotinib 150 mg daily
  • Experimental: Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)
    Participants received sorafenib 400 mg twice daily (bid) and erlotinib 150 mg tablet once daily (qd)
    Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
  • Active Comparator: Sorafenib (Nexavar, BAY43-9006) + Placebo
    Participants received sorafenib 400 mg twice daily (bid) and matching erlotinib placebo 150 mg tablet once daily (qd)
    Intervention: Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
732
December 2014
April 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients > 18 years of age
  • Patients who have a life expectancy of at least 12 weeks
  • Patients with histological or cytologically documented HCC
  • Patients must have at least one tumor lesion that meets both of the following criteria:

    • The lesion can be accurately measured in at least one dimension according to response evaluation criteria in solid tumors (RECIST)
    • The lesion has not been previously treated with local therapy
  • Patients who have an ECOG PS (Eastern Cooperative Oncology Group Performance Status) of 0 or 1
  • Cirrhotic status of Child-Pugh class A.
  • Patients who give written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time.

Exclusion Criteria:

  • History of cardiac disease: congestive heart failure > New York Heart Association (NYHA) class 2; active coronary artery disease (CAD); cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin), or uncontrolled hypertension. Myocardial infarction more than 6 months prior to study entry is permitted.
  • Abnormalities of the cornea based on history (e.g. dry eye syndrome, Sogren's syndrome) including congenital abnormality (e.g. Fuch's dystrophy), abnormal slit-lamp examination using a vital dye (e.g. fluorescein, Bengal-Rose), and/or an abnormal corneal sensitivity test (Schirmer test or similar tear production test).
  • History of interstitial lung disease (ILD).
  • Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.
  • Previous treatment with yttrium-90 spheres
  • Any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study.
  • Uncontrolled ascites (defined as not easily controlled with diuretic treatment)
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Austria,   Belgium,   Brazil,   Bulgaria,   Canada,   Chile,   China,   Colombia,   France,   Germany,   Greece,   Hong Kong,   Israel,   Italy,   Korea, Republic of,   New Zealand,   Peru,   Poland,   Russian Federation,   Singapore,   South Africa,   Spain,   Taiwan,   United Kingdom
 
NCT00901901
12917, 2008-006021-14
Yes
Bayer
Bayer
Not Provided
Study Director: Bayer Study Director Bayer
Bayer
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP